LUND Sweden, Dec. 7, 2020 /PRNewswire/ -- Immunovia AB
(publ) ("Immunovia") a near-commercial stage diagnostics company
developing ground-breaking antibody-based multiplex microarray
technology platform called IMMray™ for the early detection of
cancer, announced today that Julie
Silber, Senior Director of Investor Relations has stepped
down from her position to pursue other opportunities effective
November 30, 2020. CEO, Patrik Dahlen will assume the Investor Relations
duties immediately.
"We appreciate the many contributions Julie made since joining
the Immunovia team as Director of IR. We would like to thank Julie
for her time at Immunovia," stated Patrik
Dahlen, CEO of Immunovia.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-announces-investor-relations-changes,c3250432
The following files are available for download:
https://mb.cision.com/Main/13121/3250432/1345224.pdf
|
Press release
(PDF)
|